Federal health officials reduced the number of routine childhood vaccine recommendations from 17 to 11 in a policy change announced by HHS and the CDC, a move implemented without the usual ACIP advisory process. The revised guidance moves several vaccines — including influenza, RSV and hepatitis A/B — to a shared‑decision or high‑risk recommendation framework rather than universal childhood status. The Biotechnology Innovation Organization (BIO) publicly condemned the decision as unscientific and said the change risks undermining public confidence. BIO warned the shift could reduce vaccination rates and increase disease risk among children. Drugmakers and clinician groups have also expressed concern, noting the abrupt process and potential public‑health consequences. The policy change is expected to reverberate through vaccine manufacturers, pediatric practice patterns and payer coverage discussions as stakeholders seek clarity and potential legal or procedural challenges.